Multidomain trials to prevent dementia: addressing methodological challenges

Manuel Montero-Odasso1,2,3, G Y Zou4, Nellie Kamkar5

  • 1Schulich School of Medicine and Dentistry, Department of Medicine and Division of Geriatric Medicine, The University of Western Ontario, London, ON, Canada. mmontero@uwo.ca.

Abstract

Insights

Multidomain lifestyle interventions show promise for dementia prevention. Standardly tailored trial designs offer a pragmatic approach to evaluate these complex interventions and their impact on cognitive health.

Area of Science:

  • Gerontology
  • Neuroscience
  • Public Health

Background:

  • Multidomain lifestyle interventions targeting multiple dementia risk factors show promise.
  • Designing trials to evaluate individual and combined intervention efficacy presents methodological challenges.
  • Determining intervention efficacy is crucial for individuals, healthcare payers, and resource allocation.

Purpose of the Study:

  • To elaborate on methodological challenges in evaluating multidomain dementia prevention trials.
  • To compare standardly tailored designs with fully factorial designs.
  • To propose analytical strategies to bolster causal inferences in dementia risk reduction studies.

Main Methods:

  • Utilizing a standardly tailored design with two arms: one with tailored multidomain interventions and another with active controls.
  • Comparing the standardly tailored approach with fully factorial designs, discussing advantages and disadvantages.
  • Employing sensitivity and exploratory analyses, including risk reduction scores, to assess the impact of risk factor modification.

Main Results:

  • Standardly tailored designs provide pragmatic and feasible evaluations of multidomain dementia prevention interventions.
  • Challenges exist in post hoc quantification of specific intervention components responsible for cognitive improvements.
  • Risk reduction scores can measure changes in risk factor number or severity within study arms.

Conclusions:

  • Standardly tailored designs are practical for evaluating multidomain dementia risk reduction interventions.
  • Sensitivity and exploratory analyses of risk factor reduction can strengthen causal inferences between intervention and cognitive outcomes.
  • This methodology supports understanding the impact of modifying multiple risk factors on cognitive health.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
259
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
162
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
663
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.3K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.1K
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
391